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Objective 
The purpose of the study was to determine the angiogenic capacity of sera in early and late 
pregnancy and in umbilical blood serum after childbirth, and to define how angiogenic properties 
assessed in a functional in vitro test are related to individual angiogenic proteins in six women with 
pre-eclampsia and in six healthy pregnant controls.  
Methods 
Maternal first and third trimester serum samples, and umbilical blood samples after childbirth were 
tested in an in vitro human adipose stromal cell – human umbilical vein endothelial cell (hASC-
HUVEC) vasculogenesis/angiogenesis assay. The angiogenic properties of the samples were 
measured by quantifying tubule formation. Concentrations of total placental growth factor (PlGF),  
total vascular endothelial growth factor (VEGF), soluble fms-like tyrosine kinase 1 (sFlt-1) and 
soluble endoglin (sEng) were determined by immunoassay. 
Results 
First-trimester maternal sera of both groups had a stimulatory effect on angiogenesis in vitro and 
levels of angiogenic proteins did not differ between the groups. Third-trimester maternal sera in the 
pre-eclampsia group had an inhibitory effect on tubule formation, while those from normal 
pregnancies remained stimulatory. Compared with the first trimester there was a significant change 
in the concentrations of angiogenic proteins toward an anti-angiogenic state in pre-eclampsia. 
Umbilical blood serum exhibited strong anti-angiogenic effects without a significant difference 
between groups.  
This is the post print version of the article, which has been published in Angiogenesis. 
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Conclusions 
Third-trimester serum of pre-eclamptic patients is anti-angiogenic. This phenomenon is not yet 
present in the first trimester. Umbilical blood serum shows inhibitory effects on angiogenesis after 
normal as well as pre-eclamptic pregnancy. 
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Introduction 
There have been several studies on pro- and anti-angiogenic factors and their differences in normal 
pregnancies and in women with pre-eclampsia [1,2]. The most studied proteins are pro-angiogenic 
factors such as placental growth factor (PlGF) and vascular endothelial growth factor (VEGF) and 
anti-angiogenic factors such as soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin 
(sEng) [1,3]. Even in normal pregnancies changes in favour of anti-angiogenic proteins in the third 
trimester have been observed, but in pre-eclampsia the imbalance between pro- and anti-angiogenic 
proteins is stronger and a change in concentrations of these proteins toward an anti-angiogenic state 
has been seen to exist several weeks before the onset of clinical disease [4,5]. There are fewer 
studies on angiogenesis in connection with umbilical blood after pre-eclamptic pregnancy. Pre-
eclampsia seems to have an effect on the umbilical cord itself and on cord blood, as structural 
changes have been found in endothelia of umbilical vessels and increased concentrations of s-Flt-1 
in umbilical blood after childbirth [6,7].  
The net angiogenic capacity of serum can be measured in in vitro tests. Human primary cell-based 
in vitro assays mimic the effects in humans reliably [8,9]. In in vitro assays the endothelial cells 
form capillary-like structures (tubule formation) in response to angiogenic signals from added 
maternal serum [10]. In contrast to quantitative tests involving measurement of concentrations of 
single specific pro- and anti-angiogenic factors, in vitro angiogenesis tests reveal functional 
capabilities of tested samples to promote, maintain or inhibit tubule formation [8,10]. In addition, 
they provide quantitative information on the extent of tubule formation [8,11]. The in vitro 
vasculogenesis/angiogenesis human adipose stromal cell – human umbilical cord vein endothelial 
cell (hASC-HUVEC) test offers a possibility to study the effects of serum on angiogenesis 
(formation of new blood vessels from existing ones) and vasculogenesis (de novo blood vessel 
generation from vascular progenitor cells) [8,11]. 
In the present study we wanted to assess inter-group differences and longitudinal changes in 
angiogenic capacity of maternal serum during pregnancy in healthy women and in women with pre-
eclampsia, utilising the hASC-HUVEC test. Another aim was to investigate how the angiogenic 
capacity of maternal serum is associated with known pro- and anti-angiogenic factors. Furthermore, 
we wanted to evaluate the angiogenic capacity of umbilical blood samples after pre-eclampsia and 
healthy pregnancy.  
 
Materials and methods 
Ethics statement 
This study was approved by the Ethics Committee of Pirkanmaa Hospital District, Tampere, 
Finland (permit number R11088). Written informed consent was obtained from the women agreeing 
to participate in the study. The use of human adipose stromal cells (hASCs) and human umbilical 
cord endothelial cells (HUVECs) was separately approved by the Ethics Committee of Pirkanmaa 
Hospital District, Tampere, Finland (permit numbers R03058 and R08028, respectively).  
Study population 
This was a cross-sectional research project where the study population consisted of six primiparous 
women with pre-eclampsia and six controls. All women gave two blood samples during pregnancy 
and an umbilical blood sample after childbirth in 2011–2014.  The women were recruited to the 
study during the third trimester of pregnancy. The inclusion criteria for healthy controls were: blood 
pressure < 140/90 mmHg, urine dip stick test negative for proteinuria and previously uncomplicated 
singleton pregnancy. Hypertension later in pregnancy was an exclusion criterion. Early-gestation 
serum samples from both groups were obtained from the National Institute for Health and Welfare, 
where maternal sera from first-trimester screening was stored. The samples had been taken between 
the ninth and eleventh weeks of gestation. Gestational age was calculated on the basis of the last 
menstruation and corrected if necessary at first-trimester screening ultrasonography. 
The definition of pre-eclampsia was that of the International Society for the Study of Hypertension 
in Pregnancy (ISSHP) in 2000. Systolic blood pressure should be ≥ 140 mmHg or diastolic blood 
pressure ≥ 90 mmHg on at least two occasions 4 h apart after 20 weeks of gestation in previously 
normotensive women, with proteinuria of 300 mg or more in 24 h [12]. Pre-eclampsia was defined 
as severe if HELLP syndrome (haemolysis, elevated levels of liver enzymes and low platelet count), 
eclampsia or exceptionally high blood pressure (> 160 mmHg systolic or > 110 mmHg diastolic) 
appeared [13,14]. In the study group maternal blood samples were taken at a maximum of three 
days before delivery when the patient was already hospitalized because of clinical symptoms of pre-
eclampsia. Cord blood samples were taken after delivery of the placenta in both groups. There was 
no separation between umbilical arterial and venous blood in the cord samples. The serum samples 
were frozen and conserved at -70 ͦC until assay. Blood tests for haemoglobin level, platelet count 
and alanine aminotransferase level were carried out at admission for the women with pre-eclampsia. 
Baseline demographic details and data on pregnancy outcome were collected from the hospital 
maternity records.  
Deviation from normal growth (mean weight of newborns at the same gestational age) was 
determined for all newborns according to national weight curves [15]. Small-for gestational-age 
(SGA) was defined as birth weight more than two standard deviations below the mean.  
Immunoassays 
The concentrations of sFlt-1, PlGF, VEGF and sEng were determined in all samples by using 
ProcartaPlex assays (Thermo Fisher Scientific) according to the manufacturer’s instructions. 
Briefly, samples were centrifuged at 1000 × g for 10 min before use in the assay. The samples were 
not diluted. Antigen standards and magnetic beads were prepared according to the manufacturer’s 
instructions. Samples and standards were then added to the beads and incubated with shaking for 2 
hours at room temperature. The detection antibodies were added and incubated for 30 min at room 
temperature. To stain the proteins, streptavidin-PE was added and incubated for 30 min at room 
temperature, after which the beads were analysed in reading buffer. The results were analysed with 
Bio-plex200 (Bio-Rad, California, USA) and Bio-Plex Manager™ 6.0 software (Bio-Rad). 
Concentrations were obtained in pg/ml. Standard concentrations for VEGF were 5.74–23,500 
pg/ml, for sFlt-1 49–200,000 pg/ml, for sEng 0.61–2500 pg/ml and for PlGF 1.66–6800 pg/ml. If 
the result obtained was lower or higher than the range of the standards, a fixed concentration above 
or below the standards was used in analysis of the results. The concentration used for sEng was 
2550 pg/ml when the result was over the standard range and for PlGF 1 pg/ml when the result was 
lower than the lowest standard. The result of the VEGF and PlGF assays can include also the bound 
version of these growth factors and hence the concentration result should be considered as total 
concentration.  
Cells 
Human adipose tissue samples were obtained from waste material from surgical operations and 
human umbilical cords from uncomplicated pregnancies were received after Caesarean sections. 
Isolation of HUVECs from umbilical cord veins was performed as described earlier (Sarkanen et al. 
2012) using 0.05% collagenase I (Gibco, Thermo Fisher scientific, Waltham, USA) inserted into the 
umbilical vein [16]. Isolation of hASCs was performed as described earlier (Sarkanen et al. 2012) 
using 0.15% Collagenase type I (Gibco) [16]. HUVECs were cultured in EGM-2 medium (Lonza, 
Basel, Switzerland) and hASCs in hASC medium (Table 1). Cells were negative for mycoplasma 
contamination, tested by using MycoAlert™ kits (Lonza). 
In vitro vasculogenesis/angiogenesis test 
To study the angiogenic potency, i.e., bioactive growth factor content, of the serum samples, all 
three sample groups (first trimester, third trimester and umbilical blood serum samples) were 
studied by using the in vitro vasculogenesis/angiogenesis test, with a co-culture of hASCs (20,000 
cells/cm2) and HUVECs (4000 cells/cm2). The test was performed as described earlier (Virtanen et 
al. 2016) [10]. Briefly, vasculogenesis/angiogenesis was induced using vasculogenesis/angiogenesis 
test medium (Table 1) and the co-cultures were exposed to patient serum samples at a dilution of 
1:15 and cultured for six days in total with one replenishment of the growth medium. After 
exposure, the number of living cells was evaluated by using a WST-1 Cell Proliferation Reagent 
(Roche, Basel, Switzerland). Following the WST-1, the cells were fixed with ethanol and 
immunostained for vWf (Sigma Aldrich) to detect the endothelial cells and collagen IV (Sigma 
Aldrich) to detect the basement membrane of the tubules. For visualization of the tubules, 
fluorescent secondary antibodies against the primary antibodies were applied: anti-rabbit 
tetramethylrhodamine isothiocyanate (TRITC, Sigma Aldrich) for vWf and anti-mouse fluorescein 
5-isothiocyanate (FITC, Sigma Aldrich) for collagen IV. The resulting fluorescent tubules were 
imaged and analysed using an automated image analysis platform (Cell-IQ, CM-Technologies, 
Tampere, Finland). Tubule formation was quantified on the basis of the intensity of the tubular 
network formed (tubule length and branching). The obtained result was compared with the positive 
tubule formation control (highest level of tubule formation induced with stimulatory factors). 
Tubule formation was defined as stimulatory when there was more tubule formation after exposure 
of the serum sample compared with the positive tubule formation control and inhibitory when there 
was less tubule formation after exposure to serum. Values were expressed as percentage of positive 
tubule formation.  
Statistical analysis 
The data are expressed as medians and range. Differences in continuous variables between groups 
were tested by using Mann–Whitney U-tests and differences within the study group by using 
Wilcoxon’s test. Spearman’s correlation method was used to calculate correlation coefficients. 
Probabilities of less than 0.05 were considered statistically significant. Statistical analyses were 
performed by using the Statistical Package for the Social Sciences (IBM-SPSS), version 11.0. 
Results 
The characteristics of the study population are summarized in Table 2. There were two preterm 
births in the pre-eclampsia group, but none of the women had early-onset pre-eclampsia. Most 
women with pre-eclampsia had severe disease.  
In the first trimester maternal sera were stimulatory, and tubule formation was equally high in the in 
vitro test in both groups (Fig. 2). Neither were there differences between groups in concentrations 
of the individual pro- and anti-angiogenic proteins or the sFlt-1:PlGF ratio (Table 3). In both groups 
the median concentrations of PlGF were higher in maternal sera in the first trimester when 
compared with serum samples taken in the third trimester (p = 0.043) or umbilical blood serum (p = 
0.028) (Table 3).   
In contrast to the first trimester, sera from women with pre-eclampsia in the third trimester 
exhibited an inhibitory effect on tubule formation. In comparison with healthy women, tubule 
formation was significantly lower in the pre-eclampsia group (p = 0.026) (Figs. 2 and 3). Compared 
with the first trimester, there was remarkably lower (p = 0.043) tubule formation in the third 
trimester in women with pre-eclampsia, whereas in the healthy control group there was no change 
in the capacity of tubule formation (Figs. 2 and 3). In the third trimester sFlt-1 levels were higher in 
the pre-eclampsia group than in the healthy control group (p = 0.004) (Table 3) and compared with 
the first trimester sFlt-1 levels had increased (p = 0.028) and total PlGF concentrations had 
decreased (p = 0.043) in women with pre-eclampsia. In addition, the sFlt-1:PlGF and sFlt-1/VEGF 
ratios increased between the first and third trimester in the pre-eclampsia group (Fig. 1). In normal 
pregnancies sFlt-1 concentrations and the sFlt-1/VEGF ratio were similar in the first and third 
trimesters.  
Umbilical blood serum had an equally strong inhibitory effect on tubule formation in both groups. 
The inhibitory effect seen in the in vitro test was stronger in umbilical serum than in third-trimester 
maternal serum when the whole study population (i.e. including controls) was analysed as one 
group (p = 0.005). The sFlt-1/VEGF ratio was also significantly higher in umbilical than in 
maternal sera (p = 0.015). When the data was studied in separate groups, only in healthy women 
was the inhibitory effect on tubule formation stronger in umbilical than in maternal serum (p = 
0.028). There were no differences between the groups in the concentrations of individual pro- and 
anti-angiogenic proteins, or in the sFlt-1:VEGF ratio in cord sera. In women with pre-eclampsia 
sFlt-1 concentrations were significantly lower (p = 0.028) in umbilical serum than in third-trimester 
maternal serum. 
In the first trimester, total amount of pro-angiogenic proteins (VEGF and PlGF) did not show any 
correlation with the stimulatory effect seen in the in vitro test. Neither did any pro- or anti-
angiogenic protein or tubule formation measure in the first trimester have a correlation with 
baseline demographic characteristics, severity of pre-eclampsia, gestational weeks at birth or weight 
of the newborn. 
In the third trimester, when the whole study population was analysed as one group, there were 
significant negative correlations between tubule formation and sFlt-1 (r = -0.902, p < 0.001), sEng 
(r = -0.595, p = 0.041) and the sFlt-1/VEGF ratio (r = -0.748, p = 0.005). Furthermore positive 
correlations between the concentration of sFlt-1 and both systolic (r = 0.741, p = 0.006) and 
diastolic blood pressure (r = 0.849, p < 0.001) were found. A correlation between a greater 
inhibitory effect on tubule formation and a lower birth weight SD score reached statistical 
significance (r = -0.754, p = 0.050) in the pre-eclampsia group. 
In umbilical blood serum samples, when the whole study population was analysed as one group, 
there were no correlations between the concentrations of pro- and anti-angiogenic proteins versus 
tubule formation, but there were correlations between a strong inhibitory effect in in vitro tests and 
low birth weight (r = 0.790, p = 0.002), low birth weight SD score (r = 0.582, p = 0.047) and earlier 
gestational weeks at birth (r = 0.622, p = 0.031). When the same correlations were studied in the 
two separate groups, the correlations with low birth weight (r = 0.829, p = 0.042) and low birth 
weight SD score (r = 0.841, p = 0.036) remained significant in the pre-eclampsia group.  
 
Discussion 
In the present study, we demonstrated that assay of pro- and anti-angiogenic proteins is not the only 
method to measure angiogenic capacity of maternal or umbilical blood serum, but that advanced in 
vitro models provide an alternative method to study angiogenesis. We longitudinally measured 
concentrations of pro- and anti-angiogenic proteins by immunoassay and at the same time evaluated 
functional angiogenic capacity in in vitro tests in women with pre-eclampsia and in their controls 
with uncomplicated pregnancies. We assessed the overall angiogenic profile not only in women 
with symptomatic pre-eclampsia but also in the first trimester and after childbirth.     
Angiogenesis and vasculogenesis are complex processes which are regulated not only by  pro- and 
anti-angiogenic proteins but by other factors in addition [17,18]. Immunoassays give us quantitative 
information on specific proteins in maternal sera, but in order to assess overall angiogenic capacity, 
we used an additional functional approach to angiogenesis. The human cell-based in vitro 
vasculogenesis/angiogenesis test can be described as a combination of a functional and a 
quantitative test. In the in vitro assay the endothelial cells form capillary-like structures in response 
to angiogenic signals from the added maternal serum and the effect of maternal serum on tubule 
formation can be stimulatory, neutral or inhibitory. The strength of an effect can be measured as 
tubule count.  What we have gathered from the literature is that there is only one earlier study 
concerning an in vitro model of angiogenesis and pro- and anti-angiogenic proteins. In the study, in 
vitro tubule formation and sFlt-1 concentrations in maternal sera were assessed in women with pre-
eclampsia [19]. In the present study, we used an in vitro model that in addition to giving a measure 
of the effects on angiogenesis, also shows effects on vasculogenesis.       
The pro-angiogenic factors VEGF and PlGF are known to play important roles in placental 
development [18]. Angiogenic proteins have been widely studied in the first trimester in order to 
identify women destined to develop pre-eclampsia later in pregnancy, but levels of single 
angiogenic proteins have been observed to be of poor predictive value [2,20,21]. Our results are in 
concordance with these findings, since in early gestation we found no significant differences in 
functional test results or in the concentrations of pro- and anti-angiogenic proteins between the 
study groups. In our in vitro model of angiogenesis an equally strong stimulatory effect on tubule 
formation was seen in both groups in the first trimester, which reflects the pro-angiogenic state in 
early weeks of pregnancy.  Serum levels of PlGF were higher in the first trimester than later in 
pregnancy in both groups, but there was wide variation in the concentrations and we found no 
significant correlation between stimulatory effects on tubule formation and levels of pro-angiogenic 
proteins. There was no inhibition of tubule formation in the first trimester even though the levels of 
sFlt-1 were already relatively high. The results of earlier studies concerning sFlt-1 concentrations in 
the first trimester are variable, but there are more consistent findings that concentrations of sFlt-1 in 
women who subsequently develop pre-eclampsia are not significantly different from those in 
unaffected controls [22]. With a larger study population the results could be different, and it is also 
known that there are factors other than those we have measured involved in angiogenesis during the 
first trimester of pregnancy [18]. Concentrations of soluble endoglin were at the same level in both 
groups in the first trimester, as has been published earlier [23]. In summary, results concerning the 
first trimester in the present study indicate that the strong stimulatory effect seen in the in vitro test 
may better reflect the pro-angiogenic state in early gestation than levels of individual angiogenic 
proteins.   
We have earlier shown that sera in women with symptomatic pre-eclampsia are strongly inhibitory 
in our in vitro test [10]. Our finding supported the results of the study by Maynard et al., where sera 
from women with pre-eclampsia inhibited and sera from women with normotensive pregnancies 
induced tubule formation in a HUVEC-based in vitro model [19]. In the present study, the decrease 
in tubule formation was remarkable between the first and third trimester in women with pre-
eclampsia. Simultaneously there were significant changes in concentrations of sFlt-1 and PlGF 
towards a clearly anti-angiogenic balance. However, despite prevailing anti-angiogenesis, levels of 
individual pro- and anti-angiogenic proteins showed no correlation with tubule formation in the pre-
eclampsia group. This could indicate that despite a steep increase in sFlt-1 concentrations there are 
also other factors related to anti-angiogenesis in pre-eclampsia. In the present work the small study 
population and wide variation in the concentrations of pro- and anti-angiogenic proteins limits the 
finding of true associations. As in previous studies, in our study also sFlt-1 and sEng levels were 
higher in the pre-eclampsia group than in the healthy control group [2,4]. Decreases in PlGF 
concentrations and increases in sFlt-1:PlGF ratios were significant only in the pre-eclampsia group.   
The angiogenic properties of umbilical cord blood after pre-eclampsia and uncomplicated 
pregnancy have not been studied to the same extent as in maternal sera, and to our knowledge there 
are no other studies concerning the angiogenic quality of umbilical blood together with 
immunoassay measurements and in vitro test data. After childbirth, umbilical blood serum tended to 
be anti-angiogenic in the in vitro test, and it was even stronger that in maternal serum. This was 
surprising since there were no significant differences in the concentrations of pro- and anti-
angiogenic proteins (excluding higher levels of maternal sFlt-1 in the pre-eclampsia group) between 
mother and fetus. The result might be affected by the structural variety of umbilical vessels when 
compared with vessels of the same calibre in the mother. Umbilical vessels are thought to be more 
susceptible to changes in haemodynamic conditions and that might have an influence on the 
consistency of umbilical blood [7,24]. The results of studies on pro-angiogenic proteins in umbilical 
blood after pre-eclampsia and unaffected pregnancies are inconsistent [6,25]. In a recent study it 
was observed that median PlGF levels were lower in umbilical blood after pre-eclamptic pregnancy 
when compared with gestational age-matched controls [26], whereas Staff et al. reported the same 
finding as ourselves, that in the majority of samples levels of PlGF were below the lowest 
concentration standard of the immunoassay kit [6]. In the study by Sezer et al. it was found that 
there were no differences in sFlt-1 levels between a pre-eclampsia group and a control group as 
regards umbilical blood [26], as we reported, but there are also studies indicating that sFlt-1 
concentrations are higher in umbilical blood after pre-eclampsia than after unaffected pregnancies 
[6]. In the present study, concentrations of pro- and anti-angiogenic proteins in umbilical blood sera 
were similar to maternal levels, with the exception of lower sFlt-1 levels after pre-eclamptic 
pregnancy. A correlation between high sFlt-1 concentrations  and low-level tubule formation was 
found only in the healthy control group, as was also the case in maternal samples in the third 
trimester. There are probably fewer confounding factors that have an influence on angiogenesis in 
healthy pregnant women than in those with pre-eclampsia. In umbilical samples, there was also a 
correlation between a pronounced inhibitory effect in the in vitro test and low birth weight in the 
pre-eclampsia group, presumably reflecting the predominance of anti-angiogenesis present in fetal 
growth in pregnancies complicated by hypertensive disorders.  
 
Strengths and limitations 
To our knowledge, this is first study carried out to investigate an association between the results of 
an in vitro angiogenesis test and quantitative measurements of pro- and anti-angiogenic proteins at 
three different stages of pregnancy. As the proteins concerned have been extensively studied 
recently, we intended to achieve a new approach to the study of angiogenic changes during 
pregnancy in women with pre-eclampsia as well in healthy pregnant women, by using two distinct 
methods. In particular, the results of an advanced in vitro vasculogenesis/angiogenesis test give us 
new information about the overall balance of angiogenesis in complicated and healthy pregnancies. 
The study was carried out with a small number of cases, and therefore some true associations may 
not have reached statistical significance. Another limitation of this study was that some protein 
concentrations were below or above the standards in the immunoassay kits, which creates 
difficulties in comparing the study groups. The high level of sFlt-1 present in the studied serum 
samples may cross-react or interfere in the immunoassay for VEGF and PlGF. 
In conclusion, in the first trimester maternal sera had a stimulatory effect on tubule formation 
reflecting a pro-angiogenic state in early pregnancy. In the third trimester maternal sera from 
women with pre-eclampsia exhibited inhibitory properties on angiogenesis, and simultaneously 
there was change toward a more anti-angiogenic state as regards individual proteins. The 
angiogenic balance in umbilical blood sera did not differ between the study groups.   
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Table 1. Media used in the in vitro test 
Medium name Content Manufacturer 
hASC medium DMEM/F12  Gibco 
 10% human serum  PAA laboratories 
 2mM L-Glutamine Gibco 
Vasculogenesis/angiogenesis  DMEM/F12 Gibco Invitrogen 
test medium 2.56 mM L-glutamine Gibco Invitrogen 
 0.1 nM 3,3’,5-triiodo-L-thyronine 
sodium salt 
BD Biosciences 
 ITSTM Premix: BD Biosciences 
 6.65 µg insulin/ml  
 6.65 µg transferrin/ml  
 6.65 ng selenious acid/ml  
 1% Bovine serum albumin  PAA 
 2.8 mM Sodium pyruvate Gibco Invitrogen 
 200 µg/ml Ascorbic acid Sigma Aldrich 
 0.5 µg/ml Heparin Stemcell 
Technologies 
 2 µg/ml Hydrocortisone Sigma Aldrich 
 2.5 ng/ml VEGF R&D Systems 
 0.25 ng/ml FGF-β R&D Systems 
 
 
  
Table 2. Maternal characteristics and neonatal outcome 
 
aData are given as median (range). PE, pre-eclampsia; BMI, body mass index; BP, blood pressure; 
CS, caesarean section; SD, standard deviation. *p Value < 0,05, **p Value < 0,01, Mann-Whitney 
U-test 
 
 
  
  PE group (n=6) Controls (n=6) P-value 
Maternal age, yearsa 29.0 (25–33) 25 (24–34) 0.240 
BMI, kg/m2a 21.3 (19.7–22.3) 26.4 (17.9–38.2) 0.065 
Highest systolic BP, mmHga 160 (141-171) 130 (103-138) 0.009** 
Highest diastolic BP, mmHga 96 (88-110) 73 (54-88) 0.002** 
Severe pre-eclampsia (%) 5/6 (83.3)   
Gestational age, weeksa 37.5 (35.3–38.3) 40.5 (35.4–41.6) 0.065 
Mode of delivery       
      vaginal/CS, n (%) 4/2 (66.7/33.3) 3/3 (50/50)  
Birth weight, gramsa 2620 (2040–3140) 3278 (2685–4535) 0.026* 
Birth weight, SDa -1.2 [-3.1-(-0.4)] -0.5 (-1.7–1.5) 0.093 
Umbilical arterial pHa 7.23 (7.13-7.36) 7.33 (7.30-7.41) 0.052 
        
Table 3. Concentrations of angiogenic proteins in maternal serum and in umbilical blood in pre-
eclampsia and control group. 
 First trimester  Third trimester  Umbilical cord  
 PE CONTR P value PE CONTR P value PE CONTR P 
value 
VEGF (pg/ml) 2572 
(1980-
25889) 
2961 
(1875-
14003) 
 
0.94 2196 
(1417-
9281) 
1818 
(856-
17321) 
0.24 6374 
(5185-
8619) 
 
3893 
(2238-
16486) 
0.18 
PlGF (pg/ml) 144 
(1-
14155) 
120 (1-
1514) 
 
0.70 23 (1-
3535) 
 
1 (1-
1216) 
 
0.24 28 (1-
923) 
1.6 (1-
1450) 
 
0.59 
sFlt-1 (pg/ml) 3780 
(2092-
5878) 
 
5914 
(2489-
6851) 
 
0.18 11278 
(4768-
13899) 
 
1480 
(277-
6339) 
 
0.004** 1684 
(397-
6845) 
1485 
(445-
7113) 
 
0.94 
sEng (pg/ml) 2550† 2550† 1.00 2550 
(1009-
2550) 
 
1071 
(595-
2550) 
0.093 1885 
(846-
2550) 
1159 
(701-
2550) 
 
0.70 
sFlt-1/PlGF 35 
(0.2-
2092) 
44 (4-
6538) 
0,59 614 (1.4-
13064) 
734 (2-
6339) 
0.94 52 (3-
6845) 
382 (1.7-
7113) 
0.39 
sFlt-1/VEGF 1.3 
(0.1-
2.8) 
1.6 
(0.5-
2.8) 
0.70 5.6 (0.5-
8.5) 
0.5 (0.1-
5.0) 
0.041* 0.3 (0.1-
1.3) 
0.3 (0.1-
2.1) 
0.70 
tubule 
formation(%)# 
152 
(126-
158) 
135 
(70-
153) 
0.18 79 (22-
115) 
140 (72-
186) 
0.026* 26 (7-
41) 
50 (23-
146) 
0.13 
Data are given as median (range). PE, pre-eclampsia; CONTR, control; VEGF, vascular endothelial 
growth factor; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase-1; sEng; soluble 
endoglin. The concentrations of VEGF and PlGF should be considered as total concentration. #Tubule 
intensity compared to the positive tubule control. †All values were out of range above. *p Value < 0.05, 
**p Value <0.01, Mann-Whitney U-test.  
 
 
 
 
 
 
 
 
 Figure 1. S-Flt-1:VEGF ratio in maternal sera in first and third trimester. sFlt-1:VEGF ratio was 
significantly higher in pre-eclampsia group in third trimester when compared to healthy control 
group (p=0.041). There was also significant increase in sFlt-1:VEGF ratio between first and third 
trimester in pre-eclampsia group (p=0,028). Solid lines=pre-eclampsia, dashed lines=healthy. 
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 Figure 2.  Tubule formation measured as tubule count in maternal serum in first and third 
trimester of pregnancy. The decrease in tubule formation was significant between first and third 
trimester in women with pre-eclampsia (p=0,043). Solid lines=pre-eclampsia, dashed 
lines=healthy. 
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 Figure 3.  Fluorescence images of the von Willebrand factor -TRITC-stained tubules exposed to 
healthy and pre eclamptic maternal serum and cord blood. Top row: healthy serum in early 
pregnancy, late pregnancy and cord blood, all from the same mother and her child. Bottom row: 
Pre eclampic serum collected form a mother in early pregnancy and late pregnancy, and cord 
blood of the baby. Both early pregnancy samples induced strong tubule formation, in places 
forming dense tubule clumps in which the tubules are not distinguishable enough to be analyzed. 
Late pregnancy samples show that healthy serum induced more tubule formation. Both groups of 
cord blood did not show significant difference.  
 
 
 
  
Figure 4. Correlation between sFlt-1 and tubule inhibition in maternal serum samples in pre-
eclampsia and healthy control group at third trimester .Tubule inhibition was measured as tubule 
formation meaning the lower the tubule count, the stronger the inhibition. The correlation was 
significant when whole study population was analyzed as one group (r=-.902, p=0,000).  
 
 
